美國成癮症・藥物濫用治療市場

美國成癮症・藥物濫用治療市場 是由出版商BCC Research在2009年01月所出版的。 這份英文市場調查報告書包含193 pages 價格從美金4850起跳。

簡介

目錄

Abstract

This report:

• Details the complicated world of substance abuse including stimulants such as tobacco, amphetamines, cocaine and crack, depressants such as sedatives and hypnotics, alcohol and opiates, and hallucinogens
• Identifies therapeutics and diagnostics for drug abuse treatment and makes U.S. market forecasts for these products over a 5-year period, from 2008 to the end of 2013
• Includes current and potential market drivers
• Discusses up-and-coming products that may make a significant contribution to the market
• Profiles market participants and looks at market shares.

STUDY GOALS AND OBJECTIVES

This BCC Research report details the complicated world of substance abuse. The increased prevalence of substance abuse poses a threat to the health and welfare of many populations throughout the world. Recreational drugs play a major role in crime and corruption and are becoming a larger problem each year. Abuse of prescription drugs and alcohol places a heavy burden on health resources due to the subsequent medical problems. Breaking the substance abuse cycle is a difficult and tedious process. Pharmaceutical manufacturers have developed several products to assist in recovery from substance abuse. Those products are detailed in the report. Also discussed are the products to help employers, parents, social workers, and other groups and organizations detect for substance abuse.

The objectives of the study are to heighten the awareness of drug abuse and to identify preparations, tests, and important advancements in the drug abuse treatment arena. The study analyzes the new therapeutics and diagnostics for drug abuse treatment from a current standpoint as well as what is on the horizon. Manufacturers of pharmaceutical products have been reluctant to invest valuable time and resources into this market because of the issues facing the market. As a result, the problem of drug abuse continues to grow.

SCOPE OF REPORT

The study is designed to be a comprehensive business tool that provides an in-depth look at the world of substance abuse treatments and diagnostics. The geographic scope of the report is the United States. The report identifies the different drugs of addiction; gives a brief explanation of the drug; outlines the characteristics of the drug; cites complications of the drug; presents current diagnostic testing; outlines current treatments, market size, and market participants; and discusses new developments and research. The report describes the industry in detail, its relationship to the healthcare industry, its economic consequences, its participants, and its trends for the future.

The following areas are addressed in this report:

• Stimulants
  • Tobacco
  • Amphetamines
  • Cocaine, Crack
  • Depressants
• Sedatives and Hypnotics
  • Alcohol
  • Opiates
  • Hallucinogens
• Diagnostic Testing
  • Point-of-Care
  • Home

Each subsegment is discussed in detail, describing the drug, complications, diagnostic testing, therapeutic management, and current products on the market to treat abuse of the drug.

INFORMATION SOURCES

The information and analysis presented in this BCC Research report are based on extensive firsthand interviews with primary executives, product managers, and clinical specialists in the area of addiction and substance abuse. Background information was obtained from various government, business, medical journal, psychiatric journal and trade magazines; from statistics from the National Center on Drug Abuse; and from interviews with psychiatrists, psychologists, drug treatment counselors, and nurses. Key information from published literature was used to conduct interviews with industry participants to validate and obtain expert opinions on current and future trends. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as to formulate market projections.

All market data pertain to the U.S. market at the manufacturer' s level. Data are expressed in 2008 U.S. dollars. The base year was 2007. Historical data are provided for 2006 and forecast data are provided for 2008 and 2013. Historical, base year and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2007 base year.

Table of Contents

U.S. Markets for Addiction & Substance Abuse Treatment

Chapter-1: EXECUTIVE SUMMARY

• SUMMARY TABLE U.S. MARKET FOR ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)
• SUMMARY FIGURE U.S. MARKET FOR ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, 2006-2013 ($ MILLIONS)

Chapter-2: INDUSTRY OVERVIEW

• HISTORY OF SUBSTANCE ABUSE
• OVERVIEW OF SUBSTANCE ABUSE
• OVERVIEW OF SUBSTANCE ABUSE (CONTINUED)
• MODELS OF ADDICTION
• ADDICTION THEORIES
• Biological Theories
• Psychological Theories
• Sociocultural Theories
• PATTERNS OF SUBSTANCE ABUSE
• RISK FACTORS
• ADDICTIVE PROCESS
• DEMOGRAPHIC TRENDS
  • TABLE 1 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2005-2007 (MILLIONS)
  • FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2006-2008 (MILLIONS)
  • TABLE 2 WORLDWIDE POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2005-2007 (MILLIONS)
  • FIGURE 2 WORLDWIDE POPULATION BY SELECTED AGE GROUPS, 2006-2008 (MILLIONS)
• TOBACCO USE
  • FIGURE 3 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER BY TYPE OF TOBACCO USE, 2005 (MILLION PEOPLE)
• Age
  • FIGURE 4 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER, 2005 (%)
• Gender
  • FIGURE 5 PAST MONTH OF TOBACCO USE FOR MALES AND FEMALES AGED 12 OR OLDER, 2005 (%)
• Race/Ethnicity
  • FIGURE 6 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, 2005 (%)
• Education
  • FIGURE 7 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2006 (%)
• College Students
  • FIGURE 8 PAST MONTH OF TOBACCO USE ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18 TO 22, ESTIMATED, 2006 (%)
• Employment
  • FIGURE 9 PAST MONTH OF TOBACCO BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2006 (%)
• Geographic Area
  • FIGURE 10 PAST MONTH OF TOBACCO USE BY GEOGRAPHIC REGION BASED ON POPULATION DENSITY FOR AGES 12 OR OLDER, ESTIMATED, 2006 (%)
• Association of Tobacco Use with Illicit Drug and Alcohol Use
  • FIGURE 11 PAST MONTH ILLICIT DRUG, ALCOHOL USE AMONG SMOKERS AND NONSMOKERS AGED 12 OR OLDER, ESTIMATED 2006 (%)
• ALCOHOL USE
  • FIGURE 12 ALCOHOL CONSUMPTION AMONG ADULTS 18 YEARS OF AGE AND OVER, BY DRINKING STATUS: UNITED STATES, 1997 AND 2006 (%)
• Alcohol Frequency
  • FIGURE 13 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 12 OR OLDER BY FREQUENCY: UNITED STATES, 2002-2005 (%)
• Age
  • FIGURE 14 PAST MONTH ALCOHOL USE AMONG PERSONS BY AGE, 2005 (%)
• Gender
  • FIGURE 15 PAST MONTH ALCOHOL USE FOR MALES AND FEMALES AGE 12 OR OLDER, 2005 (%)
• Pregnant Women
  • FIGURE 16 PAST MONTH OF ALCOHOL USE FOR PREGNANT AND NONPREGNANT WOMEN AGED 15-44, ESTIMATED 2002-2007 (%)
• Race/Ethnicity
  • FIGURE 17 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, 2005 (%)
• Education
  • FIGURE 18 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2005-2006 (%)
• College Students
  • FIGURE 19 PAST MONTH ALCOHOL USE ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18-22, ESTIMATED, 2002 AND 2006 (%)
• Employment
  • FIGURE 20 PAST MONTH ALCOHOL USE BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2005-2006 (%)
• Geographic Area
  • FIGURE 21 ALCOHOL CONSUMPTION AMONG ADULTS 18 YEARS OF AGE AND OVER, BY UNITED STATES GEOGRAPHIC REGION, 1997 AND 2006 (%)
• Driving Under the Influence of Alcohol
  • FIGURE 22 PAST YEAR FREQUENCY OF DRIVING UNDER THE INFLUENCE OF ALCOHOL, AGES 12 OR OLDER, ESTIMATED, 2005 AND 2006 (%)
• ILLICIT DRUG USE
  • FIGURE 23 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 12 OR OLDER BY TYPE OF DRUG: UNITED STATES, 2002-2005 (%)
  • FIGURE 23 (CONTINUED)
• Age
  • FIGURE 24 PAST MONTH ILLICIT DRUG USE BY AGE, 2005 (%)
• Gender
  • FIGURE 25 PAST MONTH ILLICIT DRUG USE FOR MALES AND FEMALES AGED 12 OR OLDER, 2005 (%)
• Pregnant Women
  • FIGURE 26 PAST MONTH ILLICIT DRUG USE FOR PREGNANT AND NONPREGNANT WOMEN AGED 15-44, ESTIMATED, 2005-2006 (%)
• Race/Ethnicity
  • FIGURE 27 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, ESTIMATED, 2005
• Education
  • FIGURE 28 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2005-2006
• College Students
  • FIGURE 29 PAST MONTH ILLICIT DRUG USE BY ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18-22, ESTIMATED, 2005-2006 (%)
• Employment
  • FIGURE 30 PAST MONTH ILLICIT DRUG USE BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2005-2006 (%)
• Geographic Area
  • FIGURE 31 PAST MONTH ILLICIT DRUG USE FOR GEOGRAPHIC REGION BASED ON POPULATION DENSITY AGES 12 OR OLDER, ESTIMATED, 2005-2006 (%)
• Criminal Justice Populations
  • FIGURE 32 PAST YEAR ILLICIT DRUG USE BY PAROLE AND PROBATION STATUS AGED 18 OR OLDER, ESTIMATED, 2005-2006 (%)
• Frequency of Use
• Association with Cigarette and Alcohol Use
  • FIGURE 33 PAST MONTH ALCOHOL AND TOBACCO USE AMONG ILLICIT DRUG USERS AND NON ILLICIT DRUG USERS AGED 12 OR OLDER, ESTIMATED, 2005 - 2006
• Driving Under the Influence of Illicit Drugs
  • FIGURE 34 PAST YEAR FREQUENCY OF DRIVING UNDER THE INFLUENCE OF ILLICIT DRUGS, AGES 12 OR OLDER, ESTIMATED, 2005-2006 (MILLIONS)
• ADDICTION TREATMENT COSTS SHIFTING
• MANAGED CARE IMPACT
• PARITY LAW
• REIMBURSEMENT ISSUES
  • TABLE 3 FACILITY PAYMENT OPTIONS, BY FACILITY OPERATION AND PRIMARY FOCUS OF FACILITY, MARCH 31, 2006 (PERCENT DISTRIBUTION)
  • TABLE 4 FACILITY PAYMENT OPTIONS, BY FACILITY OPERATION AND PRIMARY FOCUS OF FACILITY: MARCH 31, 2006 (PERCENT DISTRIBUTION)
• ECONOMIC COSTS OF SUBSTANCE ABUSE
  • TABLE 5 COMPARISON OF COSTS OF MAJOR HEALTH PROBLEMS IN U.S. ($ BILLIONS)
  • TABLE 6 ECONOMIC COSTS TO SOCIETY OF DRUG ABUSE 1992-2002 ($ MILLIONS)
• STUMBLING BLOCKS TO DRUG ABUSE TREATMENT
• NEW AVENUES FOR TREATMENT OF SUBSTANCE ABUSE
  • TABLE 7 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE- ALCOHOL, COCAINE, MARIJUANA AND HEROIN
  • TABLE 7 (CONTINUED)
  • TABLE 8 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE- OTHER OPIATES, PCPS, HALUCINOGENS, AMPHETAMINES, OTHER STIMULANTS, AND TRANQUILIZERS
  • TABLE 8 (CONTINUED)
  • TABLE 9 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE- SEDATIVES, INHALANTS, AND OTHER
  • TABLE 9 (CONTINUED)
  • TABLE 10 USE OF SUBSTANCES BY AMONG PERSONS AGED 50 OR OLDER, ESTIMATED 1999 AND PROJECTED 2020 BY GENDER, RACE, AND AGE GROUP, 1999
  • TABLE 11 USE OF SUBSTANCES BY PERSONS AGED 50 OR OLDER, BY GENDER, RACE, AND AGE GROUP, 2020
• REGULATORY ISSUES
• EFFECTS OF POLY DRUG ABUSE
• POLYDRUG USE BY AGE
  • TABLE 12 ADMISSIONS REPORTING POLYDRUG ABUSE, BY AGE GROUP, 2002
• PRIMARY AND SECONDARY USE
• THE UNINSURED
  • TABLE 13 TOP 10 PRINCIPAL DIAGNOSES IN U.S. HOSPITALS WHICH HAVE UNINSURED RATES, 2002
• TREATMENT FACILITIES AND PROGRAMS
• OWNERSHIP OF SUBSTANCE ABUSE FACILITIES
  • TABLE 14 FACILITY OPERATION: NUMBER AND PERCENT DISTRIBUTION, 2002-2006
• TREATMENT COSTS
  • TABLE 15 ESTIMATED TOTAL COSTS FOR SUBSTANCE ABUSE TREATMENT AND COST PER ADMISSION, BY TYPE OF CARE: 1997 (INFLATED TO 2002 COST LEVELS)
• RESIDENTIAL REHABILITATION PATTERNS
• Culture
• Antabuse
• Basic Methods
• SELF-HELP GROUPS
  • TABLE 16 PERCENT DISTRIBUTION OF PERSONS AGED 12 OR OLDER WHO ATTENDED A “SELF-HELP” GROUP IN THE PAST YEAR BECAUSE OF THEIR ALCOHOL OR ILLICIT DRUG USE AND OF TOTAL POPULATION AGED 12 & OLDER, BY SOCIODEMOGRAPHIC CHARACTERISTICS: 2006 AND 2007
  • TABLE 16 (CONTINUED)
  • FIGURE 35 PERCENTAGES OF PAST YEAR SELF-HELP GROUP ATTENDEES AGED 12 OR OLDER, BY SUBSTANCE(S) FOR WHICH THEY ATTENDED A “SELF-HELP” GROUP, 2006 AND 2007 (%)
  • FIGURE 35 (CONTINUED)
• NATIONAL PROGRAMS FOR SUBSTANCE ABUSE
• BARRIERS TO MARKET ENTRY
• NONACCEPTANCE OF MEDICAL MODELS OF ADDICTION

Chapter-3: PHARMACEUTICAL PRODUCTS

• STIMULANTS
• NICOTINE
• Characteristics
• Effects of Use
• Complications
• Therapeutic Management
  • TABLE 17 SMOKING CESSATION PRODUCTS
• Therapeutic Management (Continued)
• AMPHETAMINES
• Characteristics
• Effects of Use
• Complications
• Therapeutic Management
  • TABLE 18 AMPHETAMINE ABUSE TREATMENTS
• COCAINE AND CRACK
• Characteristics
• Effects of Use
• Complications
• Therapeutic Management
  • TABLE 19 COCAINE ABUSE TREATMENTS
• OTHER STIMULANTS
• DEPRESSANTS
• SEDATIVES-HYPNOTICS
• Characteristics
• Effects of Use
• Complications
• Therapeutic Management
• ALCOHOL
• Characteristics
• Effects of Use
• Complications
• Complications (Continued)
• Therapeutic Management
  • TABLE 20 ALCOHOL ABUSE TREATMENTS
• OPIATES
• Characteristics
• Effects of Use
• Complications
• Therapeutic Management
• Methadone
• Other Products
• Other Products (Continued)
  • TABLE 21 OPIATE ABUSE TREATMENTS
• HALLUCINOGENS
• CANNABIS
• Characteristics
• Effects of Use
• Complications
• Therapeutic Management
• LYSERGIC ACID DIETHYLAMIDE, DIMETHYLTRYPTAMINE, MESCALINE, AND RELATED SUBSTANCES
• Characteristics
• Characteristics (Continued)
• Effects of Use
• Therapeutic Management
• OTHER HALLUCINOGENS
• INHALANTS AND OTHER DRUGS OF ABUSE
• Gases, Solvents and Nitrites
• Gases, Solvents ..... (Continued)
• Anabolic Steroids
• DIAGNOSTIC TESTING
• URINE TESTING
• SALIVA TESTING
• BLOOD TESTING
• PATCH TESTING
• HAIR TESTING
• SAMHSA POSITIVE DRUG TEST GUIDELINES
  • TABLE 22 POSITIVE DRUG TEST GUIDELINES (NG/ML)
• DRUG TESTING INDEXES
  • TABLE 23 ANNUAL POSITIVITY RATES FOR U.S. WORKERS, BY YEAR 1988-2004 (%)
  • TABLE 24 POSITIVITY RATES FOR U.S. WORKERS BY TESTING REASON, 2000-2004
  • TABLE 25 POSITIVITY RATES FOR U.S. WORKERS BY DRUG CATEGORY AS A PERCENTAGE OF ALL POSITIVE TESTS (%)
  • TABLE 25 (CONTINUED)
• POINT-OF-CARE SUBSTANCE ABUSE DIAGNOSTIC TESTING
• Tobacco Testing
  • TABLE 26 POINT-OF-CARE NICOTINE DIAGNOSTIC TEST PRODUCTS
• Jant Pharmacal
• Nymox Pharmaceuticals
• Princeton BioMeditech Corporation
• Alcohol Testing
  • TABLE 27 POINT OF CARE ALCOHOL DIAGNOSTIC TEST PRODUCTS
• Jant Pharmacal
• MEDTOX Scientific, Inc.
• OraSure Technologies
• Princeton BioMeditech Corporation
• Varian, Inc.
• Drug Testing
  • TABLE 28 POINT-OF-CARE DRUG DIAGNOSTIC TESTING PRODUCTS
• Alfa Scientific Designs
• American Bio Medica
• BioScan Screening Systems
• Biosite Diagnostics
• Inverness Medical
• MEDTOX Scientific, Inc.
• OraSure Technologies
• Phamatech
• Princeton BioMeditech
• Psychemedics Corp.
• Varian, Inc.
• Sun Biomedical
• HOME SUBSTANCE ABUSE DIAGNOSTIC TESTING
• Alcohol Testing
  • TABLE 29 ALCOHOL HOME DIAGNOSTIC TESTING PRODUCTS
• Jant Pharmacal
• Sun Biomedical Laboratories
• Drug Testing
  • TABLE 30 DRUG HOME DIAGNOSTIC TESTING PRODUCTS
• Psychemedics
• Dr. Brown' s (Elan Corporation)
• Inverness Medical Innovations, Inc.
• Phamatech
• Princeton BioMeditech
• Psychemedics
• Sun Biomedical Laboratories
• Sun Biomedical ..... (Continued)

Chapter-4: MARKET SIZE AND GROWTH

• MARKET SIZE AND GROWTH
  • TABLE 31 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 36 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, 2006-2013 ($ MILLIONS)
• PRESCRIPTION AND OVER-THE-COUNTER PHARMACEUTICAL TREATMENTS
• SMOKING CESSATION
• DRUG AND ALCOHOL ABUSE
  • TABLE 32 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS BY TREATMENT TYPE, THROUGH 2013 ($ MILLIONS)
  • FIGURE 37 U.S. MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS BY TREATMENT TYPE, THROUGH 2013 ($ MILLIONS)
• DIAGNOSTIC TESTING
• POINT-OF-CARE TESTING
• HOME TESTING
  • TABLE 33 U.S. MARKET SIZE OF SUBSTANCE ABUSE DIAGNOSTICS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 38 U.S. MARKET SIZE OF SUBSTANCE ABUSE DIAGNOSTICS, 2006-2013 ($ MILLIONS)

Chapter-5: RESEARCH AND DEVELOPMENT

• GOALS
• AREAS OF CONCENTRATION
• INDUSTRY NEEDS
• CURRENT DRUGS IN CLINICAL TRIALS
• ALCOHOL TREATMENT
• OPIATE TREATMENT
• GENERAL ADDICTION
• TOBACCO TREATMENT
  • TABLE 34 SUBSTANCE ABUSE PRODUCTS IN DEVELOPMENT
  • TABLE 34 (CONTINUED)
• MISCELLANEOUS SUBSTANCE ABUSE TREATMENT DISCOVERIES
• MISCELLANEOUS SUBSTANCE ABUSE .....(CONTINUED)
• MISCELLANEOUS SUBSTANCE ABUSE .....(CONTINUED)

Chapter-6: INDUSTRY STRUCTURE

• MARKET LEADERS
• PFIZER
• RECKITT BENCKISER
• GLAXOSMITHKLINE
• NOVARTIS
• PSYCHEMEDICS
• ORASURE TECHNOLOGIES
  • TABLE 35 TOTAL MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS, 2007
  • FIGURE 39 TOTAL MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS, 2007 (%)
  • TABLE 36 U.S. MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE DIAGNOSTICS, 2007
  • FIGURE 40 U.S. MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE DIAGNOSTICS, 2007 (%)
• INDUSTRY PARTICIPANTS BY PRODUCT TYPE
  • TABLE 37 LEADING SUBSTANCE ABUSE PHARMACEUTICAL TREATMENT AND DIAGNOSTIC TESTING MANUFACTURERS BY PRODUCT TYPE, 2008
  • TABLE 37 (CONTINUED)
• MARKET ANALYSIS
• Anti-Depressant Market
• Additional Therapies
• Opportunities
• Opportunities (Continued)

Chapter-7: COMPANY PROFILES

• GLAXOSMITHKLINE PLC
• HISTORY
• NOVARTIS PHARMACEUTICALS CORP.
• HISTORY
• ORASURE TECHNOLOGIES
• HISTORY
• PFIZER, INC.
• HISTORY
• PHAMATECH, INC.
• HISTORY
• PSYCHEMEDICS CORP.
• HISTORY
• RECKITT BENCKISER PLC
• HISTORY
• APPENDIX A- LIST OF COMPANIES
• ABBOT DIAGNOSTICS
• ABBOTT LABORATORIES
• ALFA SCIENTIFIC DESIGNS, INC.
• ALKERMES, INC.
• AMERICAN BIO MEDICA CORPORATION
• ARADIGM CORPORATION
• BARR LABORATORIES, INC.
• BIOSCAN SCREENING SYSTEMS, INC.
• BIOSITE, INC.
• BIOVAIL CORPORATION
• BRISTOL-MYERS SQUIBB COMPANY
• CARY PHARMACEUTICALS, INC.
• CELTIC PHARMA MANAGEEMNT L.P.
• CEPHALON, INC.
• CYTOS BIOTECHNOLOGY AG
• DRUG ENFORCEMENT ADMINISTRATION
• ELAN CORPORATION, PLC
• ELBION NV
• ELI LILLY & COMPANY
• ENDO PHARMACEUTICALS
• FOOD AND DRUG ADMINISTRATION
• FOREST LABORATORIES, INC.
• GLAXOSMITHKLINE PLC
• INVERNESS MEDICAL INNOVATIONS, INC.
• JANT PHARMACAL CORPORATION
• JOHNSON & JOHNSON
• JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS (JCAHO)
• MALLINCKRODT
• MEDTOX SCIENTIFIC, INC.
• NABI BIOPHARMACEUTICALS
• NATIONAL INSTITUTE ON ALCOHOL ABUSE & ALCOHOLISM
• NATIONAL INSTITUTE ON DRUG ABUSE
• NOVARTIS INTERNATIONAL AG
• NOVARTIS PHARMACEUTICALS CORP.
• NYMOX PHARMACEUTICAL CORP.
• OFFICE OF NATIONAL DRUG CONTROL POLICY
• ORASURE TECHNOLOGIES, INC.
• OVATION PHARMACEUTICALS, INC.
• PFIZER, INC.
• PHAMATECH, INC.
• PLIVA, INC.
• PRINCETON BIOMEDITECH CORP.
• PSYCHEMEDICS CORPORATION
• PURDUE PHARMA, L.P.
• RECKITT-BENCKISER PLC
• ROCHE
• SANOFI-AVENTIS
• SOMAXONE PHARMACEUTICALS, INC.
• SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION (SAMHSA)
• SUN BIOMEDICAL LABORATORIES, INC.
• TITAN PHARMACEUTICALS, INC.
• U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
• THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
• VALEANT PHARMACEUTICALS INTERNATIONAL
• VARIAN, INC.
• XANODYNE PHARMACEUTICALS, INC.
• APPENDIX B- LIST OF SUBSTANCE ABUSE TREATMENT FACILITIES
  • TABLE 38 LIST OF SUBSTANCE ABUSE TREATMENT FACILITIES
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 83 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 38 (CONTINUED)
  • TABLE 83 (CONTINUED)
  • TABLE 83 (CONTINUED)
  • TABLE 83 (CONTINUED)
  • TABLE 83 (CONTINUED)
  • TABLE 83 (CONTINUED)
  • TABLE 83 (CONTINUED)
  • TABLE 83 (CONTINUED)

相關商品

矚目市場調查報告書

全套市場調查報告定期訂閱

Market Research Report Subscription

精神病相關市場調查報告書

抗精神病藥物市場(∼2017年):金普薩(Zyprexa)·安立復(Abilify)·思樂康(Seroquel)·哲思(Geodon)專利到期，及學名藥開始販售將限制開發平台分子商業機會的可能性
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules
價格 : US $ 3500
出版日期 : 2012年01月

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年01月

憂鬱症:針對二線患者的新一代產品競爭
Product Profiles: Depression - Next generation vies for second-line patients
價格 : US $ 11400
出版日期 : 2011年11月

BCC Research發行的製藥相關市場調查報告書

全球的肝臟疾病治療藥市場

Liver Disease Treatments: The Global Market

價格 : US $ 4850

出版日期 : 2012年01月

2011年醫療市場調査評論

2011 Healthcare Research Review

價格 : US $ 850

出版日期 : 2012年01月

肺部給藥系統:技術和全球市場

Pulmonary Drug Delivery Systems: Technologies and Global Markets

價格 : US $ 4850

出版日期 : 2012年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!